KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Novartis Ag (NVS) EBITDA Margin (2016 - 2024)

Novartis Ag's EBITDA Margin history spans 13 years, with the latest figure at 32.08% for Q2 2024.

  • On a quarterly basis, EBITDA Margin rose 2152.0% to 32.08% in Q2 2024 year-over-year; TTM through Jun 2024 was 35.57%, a 2136.0% increase, with the full-year FY2025 number at 32.36%, up 345.0% from a year prior.
  • EBITDA Margin hit 32.08% in Q2 2024 for Novartis Ag, up from 24.4% in the prior quarter.
  • Over the last five years, EBITDA Margin for NVS hit a ceiling of 194.69% in Q3 2021 and a floor of 18.83% in Q1 2020.
  • Historically, EBITDA Margin has averaged 78.53% across 5 years, with a median of 65.27% in 2023.
  • The widest YoY moves for EBITDA Margin: up 12986bps in 2021, down -15280bps in 2021.
  • Tracing NVS's EBITDA Margin over 5 years: stood at 153.72% in 2020, then plummeted by -99bps to 0.92% in 2021, then skyrocketed by 11604bps to 107.48% in 2022, then tumbled by -77bps to 24.4% in 2023, then surged by 31bps to 32.08% in 2024.
  • Business Quant data shows EBITDA Margin for NVS at 32.08% in Q2 2024, 24.4% in Q4 2023, and 10.56% in Q2 2023.